electroCore (ECOR) to Post Quarterly Earnings on Wednesday

electroCore (NASDAQ:ECOR) will likely be posting its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.41) per share and revenue of $9.4940 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

electroCore (NASDAQ:ECOR) last issued its earnings results on Wednesday, May 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.59). electroCore had a negative net margin of 44.08% and a negative return on equity of 1,956.38%. The business had revenue of $9.58 million for the quarter, compared to analyst estimates of $9.01 million. On average, analysts expect electroCore to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

electroCore Stock Up 0.7%

Shares of NASDAQ ECOR opened at $6.09 on Wednesday. The stock’s 50 day moving average price is $7.91 and its two-hundred day moving average price is $6.98. electroCore has a 52-week low of $4.16 and a 52-week high of $10.49. The stock has a market capitalization of $54.93 million, a P/E ratio of -3.44 and a beta of 0.88.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $18.00.

Insider Transactions at electroCore

In other electroCore news, CFO Joshua S. Lev sold 6,667 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $9.00, for a total transaction of $60,003.00. Following the sale, the chief financial officer owned 84,889 shares of the company’s stock, valued at $764,001. This represents a 7.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas J. Errico bought 9,992 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was bought at an average cost of $5.99 per share, with a total value of $59,852.08. Following the completion of the purchase, the director owned 360,071 shares of the company’s stock, valued at approximately $2,156,825.29. The trade was a 2.85% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 7.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. NewEdge Advisors LLC boosted its position in electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock valued at $1,083,000 after buying an additional 145,047 shares during the last quarter. DRW Securities LLC bought a new stake in shares of electroCore during the fourth quarter worth $264,000. Cubist Systematic Strategies LLC acquired a new position in shares of electroCore during the first quarter valued at $153,000. Jane Street Group LLC lifted its stake in shares of electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after acquiring an additional 19,599 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in electroCore by 20.8% in the third quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock valued at $122,000 after acquiring an additional 4,231 shares during the last quarter. Institutional investors and hedge funds own 26.74% of the company’s stock.

About electroCore

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.